News
A Pennsylvania Representative is looking to ban testing mRNA vaccines on domestic animals. Representative Jacob Banta (R-Erie ...
A pioneering carbon nanodot technology, originally developed for healthcare, is now poised to transform global agriculture ...
Methylation changes in microbiome-derived cfRNA enable more accurate CRC diagnosis than traditional DNA or abundance-based ...
Brown University scholars work to turn breakthroughs and discoveries into technologies that enhance lives, placing the ...
Every living cell must interpret its genetic code—a sequence of chemical letters that governs countless cellular functions. A ...
In recent years, the FDA has approved three complement inhibitors for gMG -- eculizumab (Soliris), ravulizumab (Ultomiris), ...
Unlike the brain and spinal cord, peripheral nerve cells, whose long extensions reach the skin and internal organs, are ...
Arrowhead Pharma Kicks Off Phase III Trial for Zodasiran in Homozygous Familial Hypercholesterolemia
The firm is hoping to show that the RNAi drug can treat HoFH by reducing production of ANGPTL3, which regulates lipid and lipoprotein metabolism.
BACKGROUND: Direct reprogramming of fibroblasts to cardiomyocytes is a potentially curative strategy for ischemic heart ...
Wherefore art thou, MD-bred Romeo? The graded stakes winning Laurel Park-based 2 year old was the record-setting show-topper ...
AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks. On June 30, Morgan Stanley maintained an Overweight rating and ...
ARO-C3 is an investigational RNA interference therapeutic designed to reduce liver production of complement component 3 as a potential therapy for various complement-mediated diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results